Stockreport

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain [Yahoo! Finance]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF planned for early 2026 Neuropathic component of chronic pain linked to LPA1 activation SAN DIEGO, November 18, 2024 BUSINESS WIRE )--Contineum Therapeutics, Inc. (NASD [Read more]